[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100402410":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":39,"locations":49,"responsibleParty":96,"collaborators":98,"id":115,"slug":116,"hasResults":117,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":26,"eligibilityCriteria":120,"healthyVolunteers":117,"sex":121,"minAge":122,"maxAge":26,"enrollmentInfo":123,"targetDuration":26,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":52,"whyStopped":26,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Fudan University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"chemoradiotherapy","EXPERIMENTAL","50.4Gy\u002F28Fx; Paclitaxel plus carboplatin",[13,14],"Drug: Paclitaxel plus carboplatin","Radiation: radiotherapy",{"label":16,"type":17,"description":18,"interventionNames":19},"radiotherapy","ACTIVE_COMPARATOR","61.2Gy\u002F34Fx",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Paclitaxel plus carboplatin","Paclitaxel （45mg\u002Fm2) plus carboplatin (AUC=2); five cycles; qw",[9],null,{"type":28,"name":16,"description":29,"armGroupLabels":30,"otherNames":26},"RADIATION","Different radiotherapy dose in different groups.",[9,16],[32,35],{"name":33,"affiliation":5,"role":34},"Kuaile Zhao, doctor","STUDY_CHAIR",{"name":36,"affiliation":37,"role":38},"Xiangpeng Zheng, doctor","Huadong Hospital","PRINCIPAL_INVESTIGATOR",[40,45],{"name":33,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","18017312534","021-64175590","kuaile_z@sina.com",{"name":46,"role":41,"phone":47,"phoneExt":26,"email":48},"ying jia Deng, doctor","18017312829","dengjiaying3@sina.com",[50,69,87],{"facility":51,"status":52,"city":53,"state":54,"zip":26,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Jiangsu Cancer Hospital","RECRUITING","Nanjing","Jiangsu","China","CN",{"type":58,"coordinates":59},"Point",[60,61],118.77778,32.06167,{"lat":61,"lon":60},[64,68],{"name":65,"role":41,"phone":66,"phoneExt":66,"email":67},"Jinjun C Ye, M.D.","13585175433","jjye2004@163.com",{"name":65,"role":38,"phone":26,"phoneExt":26,"email":26},{"facility":37,"status":52,"city":70,"state":71,"zip":72,"country":55,"countryCode":56,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Shanghai","Shanghai Municipality","200000",{"type":58,"coordinates":74},[75,76],121.45806,31.22222,{"lat":76,"lon":75},[79,84,86],{"name":80,"role":41,"phone":81,"phoneExt":82,"email":83},"Xiangpeng Zheng, M.D.","8621-62483180","862162483180","zhengxp@fudan.edu.cn",{"name":85,"role":41,"phone":82,"phoneExt":82,"email":83},"Xiangpeng Zheng",{"name":85,"role":38,"phone":26,"phoneExt":26,"email":26},{"facility":88,"status":52,"city":70,"state":71,"zip":89,"country":55,"countryCode":56,"cosmosGeoPoint":90,"geoPoint":92,"contacts":93},"Fudan Universtiy Shanghai Cancer Center","200032",{"type":58,"coordinates":91},[75,76],{"lat":76,"lon":75},[94],{"name":95,"role":41,"phone":42,"phoneExt":26,"email":44},"Kuaile Zhao, MD",{"type":97,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[99,100,102,104,106,109,111,113],{"name":37,"class":6},{"name":101,"class":6},"Jiangsu Cancer Institute & Hospital",{"name":103,"class":6},"Gansu Cancer Hospital",{"name":105,"class":6},"The First Affiliated Hospital of Xiamen University",{"name":107,"class":108},"Fujian Cancer Hospital","OTHER_GOV",{"name":110,"class":6},"Taihe Hospital",{"name":112,"class":6},"Wuxi No. 4 People's Hospital",{"name":114,"class":6},"Ningbo No.2 Hospital","100402410","phase-iii-study-of-concurrent-radiotherapy-in-elderly-patients-with-esophageal-squamous-cell-carcinoma-eso-shanghai-15-100402410",false,"NCT04519905","Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)","Inclusion Criteria:\n\n* Indicates no limit on eligibility based on the sex of participants\n* The 76 years old for the minimum age a potential participant must meet to be eligible for the clinical study.\n* Esophageal squamous cell carcinoma confirmed by pathology\n* No radiotherapy, chemotherapy or other treatments prior to enrollment\n* Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, TxNxM1b (M1b only for supraclavicular lymph node metastasis) (AJCC 6th)\n* Use of an effective contraceptive for adults to prevent pregnancy\n* No severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function\n* No immunodeficiency\n* ECOG 0-1.\n* Life expectancy of more than 3 months.\n\nExclusion Criteria:\n\n* Total radiotherapy dose cannot reach 61.2Gy\u002F34Fx\n* Esophageal perforation, or hematemesis\n* History of radiotherapy or chemotherapy for esophageal cancer\n* History of surgery within 28 days before Day 1\n* History of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years)\n* Participation in other interventional clinical trials within 30 days\n* Pregnant or breast-feeding women or fertile patients\n* Drug addiction,\n* alcoholism or AIDS\n* Uncontrolled seizures or psychiatric disorders","ALL","76 Years",{"count":124,"type":125},320,"ESTIMATED","INTERVENTIONAL",[128],"NA","So far, there is no specific clinical guideline for elderly patients (\\>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy\u002F34Fx） or the chemoradiotherapy group (50.4Gy\u002F28Fx；Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.",[131,132,133],"Esophageal Squamous Cell Carcinoma","Chemoradiotherapy","Survival",[135,136,9,137,138],"esophageal squamous cell carcinoma","elderly patients","definitive radiotherapy","survival","2021-10-31",{"date":141,"type":142},"2021-11-02","ACTUAL",{"date":144,"type":142},"2020-01-06",{"date":146,"type":125},"2027-12",{"name":5,"class":6},3]